Cellegy signs revenue share deal with Ventiv

9 August 2001

Cellegy Pharmaceuticals has signed a six-year deal with the contractsales organization Ventiv Health to commercialize the latter's lead product, Anogesic (nitroglycerin ointment) for chronic anal fissures, in the USA. Ventiv will recruit and train, and the two firms will jointly manage, a dedicated sales force of 75 reps to launch and support Anogesic, and provide Cellegy with up to $10 million to commercialize the treatment.

The deal is innovative in that Ventiv will receive a substantial share of product revenues and a multi-year royalty stream, which the CSO says reflects a new trend in the pharmaceutical landscape, where emerging companies like Cellegy can keep rights to their products as well as a larger cut of the profits.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.